Issue of Equity and TVR

RNS Number : 3859H

Instem plc

12 March 2018

 

Instem plc
("Instem" or the "Company")

Issue of Equity and Total Voting Rights

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that, following the exercise of vested unapproved share options, 25,771 ordinary shares of 10p each in the Company ("Ordinary Shares") have been issued.

Application will be made to the London Stock Exchange for the admission of the 25,771 new Ordinary Shares to trading on AIM. Admission is expected to take place at 8.00am on 15 March 2018.

Total Voting Rights

Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 15,912,431 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 15,912,431.

The figure of 15,912,431 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. 

For further information, please contact:

Instem plc	[phone]
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser & Broker)	[phone]
Richard Lindley
James White
Rachel Hayes
Walbrook Financial PR
Paul Cornelius	[phone]
Sam Allen	[e-mail]
Helen Cresswell

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

 Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

To learn more about Instem solutions and its mission, please visit instem.com.

 

END

 

 

IOESFFSUEFASEDD